NORAD and ovarian serous cystadenocarcinoma: To support this finding, it was demonstrated that hsa‐miR‐155‐5p (hsa‐miR‐155) was found to be a tumor suppressor in ovarian cancer‐initiating cells,28 and the inverse coexpression correlation between NORAD and hsa‐miR‐155‐5p was revealed through Pan‐Cancer Study using nearly 400 clinical samples of ovarian serous cystadenocarcinoma (Figure 4E, http://starbase.sysu.edu.cn/panMirCoExp.php).